NSEGeneral Updates7 Sept 2026 · 7 Sept 2026, 08:34 pm
General Updates
Alembic Pharmaceuticals Limited · APLLTD
✦ AI SummaryExpansion
Alembic Pharmaceuticals Limited has informed the Exchange about the incorporation of a Wholly Owned Subsidiary (WOS) named Alembic Pharmaceuticals Global FZCO in Dubai, United Arab Emirates. The intimation was received on 7th September, 2026.
Analysis Scores
Earnings Impact5/10
Growth Catalyst6/10
Governance Concern2/10
Regulatory Risk3/10
Balance Sheet Risk4/10
Liquidity Impact7/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Alembic Pharmaceuticals Limited has informed the Exchange about General Updates: : Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Incorporation Of a Wholly Owned Subsidiary Company
Attachments (1)
📄pdf
Download →
APLLTD_07092026203031_APL_Intimation_Alembic_Pharmaceuticals_Global_FZCO_Signed.pdf
View document text
Date: 7th September, 2026
To, To,
The Manager, The Manager,
Department of Corporate Services, Listing Department,
BSE Limited National Stock Exchange of India Ltd.
P. J. Towers, Dalal Street, ‘Exchange Plaza’, Bandra Kurla Complex,
Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051
Scrip Code:533573 NSE Symbol: APLLTD
Dear Sir/Madam,
Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (‘Listing Regulations’)
With reference to the captioned matter, we wish to inform you that a Wholly Owned
Subsidiary (‘WOS’) of the Company, named Alembic Pharmaceuticals Global FZCO
has been incorporated in Dubai, United Arab Emirates, on 24th August, 2026. The
intimation regarding the incorporation of the said WOS was received by the Company
on 7th September, 2026.
The details required to be disclosed under in this regard as per Regulation 30 of the
Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-
POD2/I/3762/2026 dated January 30, 2026 (‘Master Circular’), are enclosed herewith
as Annexure – I.
We request you to kindly take the same on record.
Thanking you,
Yours faithfully,
For Alembic Pharmaceuticals Limited
Chirag K. Shukla
Company Secretary
Encl: A/a
ALEMBIC PHARMACEUTICALS LIMITED
REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123
Annexure-I
The details required to be disclosed under Regulation 30 of Listing Regulations, as
specified in Clause 1.1.A of Annexure-18 of the Master Circular:
Particulars Details
i. Name of the entity, date & Name of the entity: Alembic Pharmaceuticals
country of incorporation, etc.; Global FZCO
Date of Incorporation: 24th August, 2026
Country of Incorporation: United Arab
Emirates
ii. Name of holding company of Name of the Holding Company: Alembic
the incorporated company Pharmaceuticals Limited
and relation with the listed
entity Relation with the Company: Wholly Owned
Subsidiary
iii. Industry to which the entity Pharmaceuticals
being incorporated belongs;
iv. Brief background about the To explore new business opportunities and to
entity incorporated in terms promote, sale and distribute pharmaceutical
of products / line of product(s) of the Company.
business
v. Brief details of any Not Applicable
governmental or regulatory
approvals required for the
incorporation;
vi. Nature of consideration - Cash consideration
whether cash consideration
or share swap and details of
the same
vii. Cost of subscription / price at Cost of Subscription: AED 100,000 (Arab
which the shares are Emirates Dirham One Lakh Only).
subscribed Price: 100 shares of AED 1,000 each are
subscribed.
viii. Percentage of shareholding / Percentage of shareholding: 100%
control by the listed entity and
/ or number of shares allotted No. of shares allotted: 100 shares of AED
1,000 each
ALEMBIC PHARMACEUTICALS LIMITED
REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. ● TEL: (0265) 2280550, 2280880 ● FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com ● E-mail : alembic@alembic.co.in ● CIN : L24230GJ2010PLC061123